Studies are also underway in moderate-to-severe obstructive sleep apnea, chronic low back pain, cardiovascular and renal outcomes (a separate ~10,000-participant CVOT), and metabolic dysfunction-associated steatotic liver disease (MASLD)
In that extension, participants assigned to the 12 mg-to-maximum-tolerated-dose path averaged 30.3% body-weight reduction
Approval status may also vary by country and over time, so patients should rely on up-to-date medical advice rather than assumptions
Retatrutide metabolic benefits Retatrutide produces all of the metabolic benefits seen with Mounjaro plus additional improvements that appear unique to triple agonism: Blood sugar control: HbA1c reductions of 1.3% to 2.0% at doses of 4-12 mg in type 2 diabetes Blood pressure: Systolic blood pressure reduction of up to 14.0 mmHg at the highest dose (roughly double what Mounjaro achieves) Lipids: Non-HDL cholesterol and triglyceride reductions Prediabetes reversal: 72% of participants with prediabetes at baseline reverted to normoglycemia Inflammatory markers: Significant reductions in high-sensitivity C-reactive protein But the standout metabolic benefit, the one that has researchers most excited, is the effect on liver health
This hormone affects appetite, the stomach, and the digestive system